Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Prostatic Neoplasms × Bortezomib × 30 days × Clear all

Sponsor

Conditions

Multiple Myeloma 25 Recurrence 3 Neoplasms, Plasma Cell 3 Lymphoma 2 beta-Thalassemia 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thalassemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Neoplasms 1 Neoplasm Metastasis 1 Multi-centric Castleman's Disease 1 Macular dystrophy, corneal type 1 1 Lymphoproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphadenopathy 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoglobulin Light-chain Amyloidosis 1 HIV Infections 1 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 Anemia, Sickle Cell 1

Interventions

Magnetic Resonance Spectroscopy 24 apalutamide 23 Specimen Handling 20 Abiraterone Acetate 18 enzalutamide 17 Pluvicto 16 Prednisone 15 Radiosurgery 13 Androgen Antagonists 13 darolutamide 12 Docetaxel 11 Leuprolide 10 Biopsy 8 Triptorelin Pamoate 7 Radiotherapy 7 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 7 relugolix 6 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6 Surveys and Questionnaires 6 Nivolumab 6 Goserelin 6 cabazitaxel 5 bicalutamide 5 abiraterone 5 Standard of Care 5 Radiation 5 Glutamate Carboxypeptidase II 5 Educational Status 5 Carboplatin 5 olaparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡